vTv Therapeutics Inc. (NASDAQ:VTVT) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a research report issued to clients and investors on Tuesday. The brokerage currently has a $4.75 price target on the biotechnology company’s stock. Zacks Investment Research‘s target price points to a potential upside of 17.57% from the company’s previous close.

According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “

A number of other equities research analysts have also weighed in on VTVT. HC Wainwright set a $13.00 price objective on shares of vTv Therapeutics and gave the company a “buy” rating in a report on Thursday, May 4th. Canaccord Genuity reiterated a “buy” rating and set a $15.00 price objective on shares of vTv Therapeutics in a report on Friday. Five investment analysts have rated the stock with a buy rating, vTv Therapeutics currently has a consensus rating of “Buy” and an average target price of $14.15.

Shares of vTv Therapeutics (NASDAQ VTVT) traded down 0.2451% during trading on Tuesday, hitting $4.0301. 19,364 shares of the company traded hands. The company’s market capitalization is $132.24 million. vTv Therapeutics has a 52 week low of $4.00 and a 52 week high of $7.50. The company has a 50 day moving average price of $4.73 and a 200 day moving average price of $5.35.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.02. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.19 million. On average, analysts expect that vTv Therapeutics will post ($1.08) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “vTv Therapeutics Inc. (NASDAQ:VTVT) Stock Rating Upgraded by Zacks Investment Research” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/08/08/vtv-therapeutics-inc-nasdaqvtvt-stock-rating-upgraded-by-zacks-investment-research.html.

A number of large investors have recently made changes to their positions in VTVT. Renaissance Technologies LLC raised its stake in shares of vTv Therapeutics by 24.3% in the fourth quarter. Renaissance Technologies LLC now owns 60,900 shares of the biotechnology company’s stock worth $294,000 after buying an additional 11,901 shares during the last quarter. Candriam Luxembourg S.C.A. acquired a new stake in vTv Therapeutics during the first quarter valued at approximately $917,000. Essex Investment Management Co. LLC acquired a new stake in vTv Therapeutics during the first quarter valued at approximately $261,000. Bank of New York Mellon Corp raised its stake in vTv Therapeutics by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 1,305 shares in the last quarter. Finally, Sphera Funds Management LTD. raised its stake in vTv Therapeutics by 50.0% in the first quarter. Sphera Funds Management LTD. now owns 300,000 shares of the biotechnology company’s stock valued at $1,965,000 after buying an additional 100,000 shares in the last quarter. Institutional investors own 11.12% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.